Published online Sep 24, 2015. doi: 10.5500/wjt.v5.i3.81
Peer-review started: April 14, 2015
First decision: May 13, 2015
Revised: May 27, 2015
Accepted: June 18, 2015
Article in press: June 19, 2015
Published online: September 24, 2015
Lymphomas constitute the second most common indication for high dose therapy (HDT) followed by autologous hematopoietic cell transplantation (auto-HCT). The intent of administering HDT in these heterogeneous disorders varies from cure (e.g., in relapsed aggressive lymphomas) to disease control (e.g., most indolent lymphomas). Regardless of the underlying histology or remission status at transplantation, disease relapse remains the number one cause of post auto-HCT therapy failure and mortality. The last decade has seen a proliferation of clinical studies looking at prevention of post auto-HCT therapy failure with various maintenance strategies. The benefit of such therapies is in turn dependent on disease histology and timing of transplantation. In relapsed, chemosensitive diffuse large B-cell lymphoma (DLBCL), although post auto-HCT maintenance rituximab seems to be safe and feasible, it does not provide improved survival outcomes and is not recommended. The preliminary results with anti- programmed death -1 (PD-1) antibody therapy as post auto-HCT maintenance in DLBCL is promising but requires randomized validation. Similarly in follicular lymphoma, maintenance therapies including rituximab following auto-HCT should be considered investigational and offered only on a clinical trial. Rituximab maintenance results in improved progression-free survival but has not yet shown to improve overall survival in mantle cell lymphoma (MCL), but given the poor prognosis with post auto-HCT failure in MCL, maintenance rituximab can be considered on a case-by-case basis. Ongoing trials evaluating the efficacy of post auto-HCT maintenance with novel compounds (e.g., immunomodulators, PD-1 inhibitors, proteasome inhibitors and bruton’s tyrosine kinase inhibitors) will likely change the practice landscape in the near future for B cell non-Hodgkin lymphomas patients following HDT and auto-HCT.
Core tip: Prevention of disease-relapse is an unmet medical need in B-cell non-Hodgkin lymphomas (NHL) undergoing autologous hematopoietic cell transplantation (auto-HCT). In this review, are summarized potentially paradigm changing advances in post auto-HCT, maintenance strategies in B-cell NHL.
- Citation: Epperla N, Fenske TS, Hari PN, Hamadani M. Recent advances in post autologous transplantation maintenance therapies in B-cell non-Hodgkin lymphomas. World J Transplant 2015; 5(3): 81-88
- URL: https://www.wjgnet.com/2220-3230/full/v5/i3/81.htm
- DOI: https://dx.doi.org/10.5500/wjt.v5.i3.81
Hodgkin and non-Hodgkin lymphomas (NHL) collectively constitute the second most common indication for high dose therapy (HDT) and autologous hematopoietic cell transplantation (auto-HCT)[1]. In chemotherapy responsive relapsed lymphoid malignancies auto-HCT can provide long-term disease control, while avoiding the immunologic complications and delayed immune reconstitution associated with allogeneic HCT.
The curative potential of auto-HCT or the expected duration of disease control in lymphoid malignancies varies depending on the histological subtype, number of prior therapy lines and depth of remission prior to HDT. The role of auto-HCT as a potentially curative option in relapsed, chemosensitive diffuse large B-cell lymphoma (DLBCL) is well-defined. The PARMA trial[2] established that salvage chemotherapy and auto-HCT provided a significantly better event-free survival (EFS) and overall survival (OS) in subjects randomized to the HDT arm. Several registry based[3-6] and prospective studies in the rituximab-era[7] have reproduced these results. In contrast, auto-HCT when applied upfront for mantle cell lymphoma (MCL)[8], or for relapsed, chemosensitive patients with follicular lymphoma (FL) is generally not considered a curative modality.
Regardless of the underlying histology or remission status at transplantation, disease relapse or progression remains the number one cause of post auto-HCT therapy failure and mortality. Prevention of disease relapse following auto-HCT in lymphoid malignancies therefore remains an unmet medical need. Disease relapse following auto-HCT occurs via two possible mechanisms. Most patients relapse likely due to the proliferation of a resistant clone of lymphoma cells (or stem cells) surviving the HDT. A minority may experience relapse due to re-infusion of an autograft contaminated by lymphoma cells[9]. In order to circumvent the problem of autograft contamination by lymphoma cells, several studies have examined the role of ex vivo purging (by monoclonal antibodies, CD34+ cell selection, etc.)[10,11] and in vivo purging (e.g., rituximab with mobilization)[12,13] of autologous stem cell products. However, randomized data do not demonstrate improved outcomes with purged auto-HCT[14]. Similarly intensifying HDT with radioimmunotherapy based conditioning regimens[15] have likewise not demonstrated improved HCT outcomes. A handful of studies have looked at tandem auto-HCT following by reduced-intensity allogeneic HCT in lymphoid malignancies[16,17]. However no randomized data are available to support the use of this approach. Moreover advanced age, comorbidities and suitable donor availability makes such a tandem HCT approach theoretically applicable to only a small subset of lymphoma patients.
Over the last decade several studies have shown improved outcomes with maintenance immunotherapies applied after conventional chemoimmunotherapies in patients with lymphoid malignancies[18-20]. Owing to the excellent safety profile of maintenance immunotherapies in the non-transplant setting, this modality has now been investigated post auto-HCT in lymphoid malignancies. In this article we review the role of post auto-HCT maintenance therapies in B cell NHL, along with overview of novel agents that likely will serve as future maintenance strategies in the post auto-HCT setting.
Of DLBCL patients who relapse after auto-HCT, a vast majority relapse early post-transplant. In a recent Center for International Blood and Marrow Transplant Research (CIBMTR) study[5], nearly three quarter of relapses in DLBCL were seen within the first 9 mo following autoHCT. A landmark analysis of DLBCL patients surviving the first 9 mo post-transplant without relapse/progression, showed a 5-year progression-free survival (PFS) probability of > 80%, suggesting that an effective strategy to prevent early DLBCL relapses post auto-HCT would theoretically translate into significant improvements in patient outcomes.
Studies evaluating the role of maintenance therapies in DLBCL are summarized in Table 1[21-26]. A small case series by Lim et al[21] (n = 15) provided preliminary evidence for maintenance in DLBCL post HCT. In this study post auto-HCT rituximab maintenance in high risk NHL for 2 years (once every 3 mo) provided a relapse-free survival of 100% and OS of 80% at 5.5 years (Table 1). Subsequently, in a small prospective study (n = 12), in vivo graft purging and post auto-HCT maintenance with rituximab in high risk DLBCL resulted in 3 year PFS of 83% and OS of 100%[22].
| Ref. | Study design | Maintenance schedule | n | % CS at HCT | PFS/EFS (%) | OS (%) | Comments |
| Lim et al[21] | Retrospective | Rituximab 375 mg/m2 (q 3 mo for a total of 8 doses) | 15 | 100 | - | 80 | Relapse free survival 100% (5.5 yr) |
| (5.5 yr) | |||||||
| Zhang et al[22] | Single arm prospective | Rituximab 375 mg/m2 (q 3 mo for 2 yr) | 12 | 100 | 83 | 100 | Prolonged hypogammaglobinemia in 2 patients |
| (3 yr) | (3 yr) | ||||||
| Tsirigotis et al[23] | Retrospective | Rituximab 375 mg/m2 (80% q wk and 20% q mo) | 19 | 79 | NR | NR | Compared to controls, maintenance improves PFS and OS |
| Haioun et al[24] | Randomized prospective | Rituximab 375 mg/m2 (weekly for 4 doses) | 269 | 84.5 | 80 (R) vs 71 (O) | - | Patients underwent autoHCT upfront in first remission |
| R = 139, O = 130 | (4 yr) | ||||||
| Gisselbrecht et al[25] | Randomized prospective | Rituximab 375 mg/m2 (q 8 wk for 1 yr) | 242 | 100 | 52 (R) vs 56 (O) | 61 (R) vs 65 (O) | 4 yr EFS was 52% for Rituximab arm while 53% for observation arm |
| R = 122, | (4 yr) | (4 yr) | |||||
| O = 120 | |||||||
| Armand et al[26] | Prospective phase II | Pidilizumab 1.5 mg/kg (q 42 d for 3 cycles) | 66 | 91 | 72 | 85 | ORR was 51% (CR of 34%) in pts with measurable disease after autoHCT |
| (16 mo) | (16 mo) |
These studies paved way for a large prospective randomized study, in which high-risk DLBCL (n = 269) patients after undergoing an upfront autoHCT consolidation in first remission, were randomized to a brief rituximab course (four weekly doses) vs observation. In patients who achieved a complete remission (CR) following HDT, this brief maintenance rituximab exposure provided statistically significant superior EFS (Table 1)[24]. Since all DLBCL patients underwent an auto-HCT in first remission in this trial (a scenario that would not be considered standard-of-care today), caution must be exercised in extrapolation of these data to relapsed DLBCL patients undergoing auto-HCT. Of note, quality of life (QOL) assessments in this study showed rapid recovery (as early as day 100) in all the tested QOL subdomains after auto-HCT and rituximab maintenance did not negatively influence the QOL outcomes[27].
The more clinically relevant question of rituximab maintenance in DLBCL patients after failing first line therapies was addressed in the collaborative trial in relapsed aggressive lymphoma (CORAL) study. In this trial (after an initial randomization of patients between two different salvage therapies), a second randomization of relapsed DLBCL patients after auto-HCT to either rituximab maintenance (every 2 mo for 1 year) or observation alone was performed (Table 1). Rituximab maintenance in this study provided no benefit in terms of EFS, PFS or OS. However an unplanned subset analysis suggested a possible benefit of maintenance rituximab in female patients[25]. This finding likely is a reflection of less rapid rituximab clearance in females, which in turn leads to higher blood concentrations of rituximab[28]. This observation could suggest a benefit of rituximab post auto-HCT in female subjects (and possibly in males using higher doses of rituximab), but this hypothesis needs further investigation. In addition to a lack of randomized data supporting using of maintenance rituximab for relapsed DLBCL, uncontrolled data suggest prolonged hypogammaglobulinemia extending beyond 2 years when using this approach in the post auto-HCT setting[21,22].
Advances in our understanding of tumor biology have led to the development of novel targeted therapies in DLBCL. Programmed death 1 (PD-1) is a T cell co-receptor that binds to the ligand B7 to maintain an immunosuppressive tumor microenvironment. PD-L1 is expressed on suppressor immune cells in the tumor microenvironment and in a subset of DLBCL[29-32] where it may alter the composition and function of tumor-infiltrating lymphocytes[33], and therefore represents a valid therapeutic target. Early after auto-HCT, a majority of the circulating leukocytes are natural killer cells, CD45RO+ memory/effector cells and monocytes, which comprise anti PD-1 monoclonal antibody target populations and whose presence has been associated with a favorable prognosis in DLBCL[34-36]. In DLBCL patients, post auto-HCT PD-1 blockade may prevent PD-1 mediated exhaustion of antitumor lymphocytes, leading to eradication of residual disease and improvement in transplant outcomes. In a multicenter phase II trial (Table 1) an anti-PD-1 monoclonal antibody, pidilizumab, was administered to patients with relapsed or refractory DBLCL following auto-HCT. The 16-mo PFS was 72% in the overall population and 70% in the subgroup of high-risk patients who had a positive positron emission tomography scan at the end of salvage therapy. Remarkably, 51% of patients with residual disease after transplant responded to the treatment, and 34% of these patients had CR without significant autoimmune toxicity[26]. Although promising, these results have not been confirmed in a prospective randomized trial yet.
Several ongoing trials are looking at maintenance post auto-HCT in DLBCL using immune modulators (NCT01241734; lenalidomide maintenance; phase I/II), PD-1 inhibitors (NCT02362997; pembrolizumab; phase II), proteasome inhibitors (NCT00992446; bortezomib in combination with vorinostat; phase II) and Bruton’s tyrosine kinase inhibitors[37] (ibrutinib maintenance in activated B-cell type DLBCL in the soon to open BMT-CTN/Alliance phase III study).
Although rituximab seems to be a feasible and safe option post auto-HCT, it does not provide improved disease control or survival outcomes and is not recommended in this setting. The preliminary results with PD-1 antibody as a post auto-HCT maintenance therapy in DLBCL are promising but require validation in a randomized setting.
Registry data from the European Group for Blood and Marrow Transplantation (EBMT)[38] and the CIBMTR show no plateau in relapse rates of FL after auto-HCT[39]. Since maintenance immunotherapies (with rituximab) in FL have shown benefit after both frontline[18] and subsequent chemoimmunotherapies[40,41], the application of rituximab maintenance following auto-HCT would also be a reasonable strategy to potentially prevent relapse.
The EBMT recently reported the efficacy and safety of rituximab, as in vivo purging before transplantation and as maintenance treatment immediately after HDT and auto-HCT in patients with relapsed FL, in a randomized prospective trial. In this study, 280 rituximab-naïve patients with relapsed FL were randomly assigned to auto-HCT with or without in vivo rituximab purging, followed by a second randomization to rituximab maintenance therapy (once every 2 mo for a total of four infusions) or observation[42]. At a median follow-up of 8.3 years, rituximab maintenance when compared to observation resulted in superior PFS at 10 years (54% vs 37%), but did not translate into an improvement in OS (73% vs 68%)[42]. In addition, maintenance rituximab was associated with a higher (albeit statistically non-significant) rate of late neutropenia. Considering the fact that this study enrolled rituximab-naïve patients, the lack of a survival benefit in this study is particularly noteworthy. It is plausible that the relatively short maintenance schedule employed in this trial resulted in a lack of survival benefit. Though randomized trials in FL in the non-transplant setting have shown no OS or PFS benefit with rituximab maintenance when using a shorter course (about 8 mo) of maintenance, as used in the EBMT study[43], the Swiss study [Swiss Group for Clinical Cancer Research (SAKK 35/98)] demonstrated superior EFS[44].
While rituximab maintenance post auto-HCT appears unlikely to improve survival of FL patients, the role of other novel approaches as maintenance therapies post auto-HCT in follicular lymphoma warrants further investigation. Ongoing post auto-HCT maintenance clinical trials involving FL patients are evaluating the role of immune modulators (NCT01035463; lenalidomide maintenance; phase I/II), and proteasome inhibitors (NCT00992446; bortezomib in combination with vorinostat; phase II) as maintenance options.
Maintenance therapies including rituximab following autoHCT should be considered investigational in patients with FL and should only be offered on a clinical trial.
Maintenance rituximab after induction chemoimmunotherapies has been shown to improve OS in older patients with MCL[20]. In MCL, prevention of relapse or progression after auto-HCT is crucial; since outcome after auto-HCT relapse is dismal with a median survival of only 23 mo[45]. Several retrospective and a few prospective studies have evaluated the potential role of post auto-HCT maintenance rituximab in MCL (Table 2)[46-49].
| Ref. | Design | Maintenance | n | % CS at HCT | PFS/EFS (%) | OS (%) | Comments |
| Lim et al[46] | Retrospective | Rituximab 375 mg/m2 (q 3 mo for 2 yr starting day + 100) | 8 | 100 | 57 | 67 | Delayed immunoglobulin reconstitution was seen in all patients and persisted beyond the rituximab maintenance period |
| Graf et al[47] | Retrospective | Rituximab 375 mg/m2 (variable dosing schedule but median doses = 8) | 157 | Almost all the patients who received MR | HR of 0.33 | HR of 0.40 | In the landmark analysis at D 100 after auto-HCT 3 yr PFS and OS were statistically better in the MR compared to the no MR group |
| R = 50, O = 107 | |||||||
| Dietrich et al[48] | Retrospective | Rituximab 375 mg/m2 (every 3 mo for 2 yr) | 72 R = 22, O = 50 | 90 (R) vs 65 (O) | 90 (R) vs 84 (O) | Patients in both the arms were well matched. The median observation time was 56 mo | |
| Gouill et al[49] | Prospective phase III | Rituximab 375 mg/m2 IV (every 2 mo for 3 yr) | 238 R = 119, O = 119 | 81.4 | 93.2 (R) vs 81.5 (O) (2 yr) | 93.4 (R) vs 93.9 (O) (2 yr) | All patients received 4 courses of R-DHAP followed by auto-HCT. The conditioning regimen of auto-HCT was R-BEAM (R=500 mg/m2) |
Dietrich et al[48] compared post auto-HCT maintenance rituximab (administered within a prospective phase II study of rituximab maintenance in B-cell lymphoma NCT 01933711), to MCL patients getting no maintenance (but transplanted during the same time period of aforementioned trial). The study showed that the 2 year PFS was significantly better in the maintenance rituximab compared to no maintenance rituximab cohort (90% and 65% respectively P = 0.014) with no difference in OS between the two arms (90% in maintenance rituximab and 84% in no maintenance rituximab) (Table 2). However, following a multivariate adjustment for other factors maintenance rituximab was strongly associated with both PFS and OS[48].
The only randomized phase III trial to study maintenance therapy in post auto-HCT setting in MCL was conducted by the LYSA, GOELAMS (Groupe Ouest Est d’Etude des Leucémies et Autres Maladies du Sang) and GELA (Groupe d’Etude des Lymphomes de l’Adulte). Patients who achieved a CR or partial remission to auto-HCT (n = 238) were randomized to maintenance rituximab (n = 119) (375 mg/m2, IV every 2 mo for 3 years) or wait and watch (WW) (n = 119) arms. The 2 year EFS and PFS were statistically different between the two arms (P = 0.015 for both) favoring the maintenance rituximab (93.2% in the maintenance rituximab arm vs 81.5% in the WW arm), however there was no difference in OS (93.4% in the maintenance rituximab arm vs 93.9% in the WW arm) (Table 2)[49]. Final data with mature follow up and complete toxicity assessment is not yet reported.
Among lymphoid malignancies, the therapeutic landscape of MCL is rapidly changing with several new agents approved for therapy in relapsed/refractory setting in the last 2-3 years. Lenalidomide has shown significant activity in relapsed/refractory MCL leading to its approval as a single agent in this patient group[50]. Fondazione Italiana Linfomi ongoing randomized phase III study is evaluating the role of lenalidomide maintenance after upfront auto-HCT consolidation in MCL (NCT02354313). Ibrutinib, another agent with known activity in relapsed MCL[51] is a potential candidate for post auto-HCT maintenance. A single arm prospective trial is administrating ibrutinib as maintenance therapy after intensive induction programs (with or without auto-HCT) (NCT02242097). Minimal residual monitoring (MRD) monitoring with polymerase chain reaction (PCR) for immunoglobulin heavy chain (IgH) and/or bcl-1 rearrangement was employed in the MCL-2 trial[52]. Pre-emptive treatment with rituximab achieved a second molecular remission in 92% of the patients (n = 26) experiencing molecular relapse (PCR+ for IgH rearrangement) post auto-HCT. After pre-emptive treatment median clinical and molecular relapse free survivals were 3.7 and 1.5 years respectively. Though strictly speaking pre-emptive therapy is not post-transplant maintenance, it is akin to the post auto-HCT maintenance therapy but needs further investigation.
Considering the poor prognosis to post auto-HCT failures in MCL, rituximab maintenance should be evaluated on a case-by-case basis (e.g., patients who would not be fit for a subsequent allogeneic transplant). In addition, rationale application of novel maintenance therapies using MRD monitoring represents a promising investigational approach for MCL patients after auto-HCT.
Moving forward, to further improve outcomes for NHL patients undergoing auto-HCT, efforts need to be focused on evaluating novel consolidation or maintenance strategies, possibly with agents not used in induction chemoimmunotherapies. Table 3 summarizes the novel agents that are currently being studied in relapsed/refractory aggressive and indolent B cell NHL. Consolidation and/or maintenance with monoclonal antibodies [to cite a few - anti CD 79b (Polatuzumab Vedotin), anti CD19 (MEDI 551) and anti CD20 (Obinutuzumab and Veltuzumab)], HDAC inhibitors (Belinostat), PDL-1 inhibitors (MPDL3280A), Bcl-2 inhibitors (ABT-199), Aurora A kinase inhibitors (Alisertib) and mTOR/PI3K inhibitors (SAR245409) in the post auto-HCT setting seems to be a potential area of further investigation.
| Drug | Mechanism of action | Ongoing trials in relapsed/refractory aggressive and indolent B cell lymphomas (not in post auto-HCT setting) |
| CD-19 antibodies (MEDI-551) | IgG1k antibody-dependent cellular cytotoxicity enhanced anti-CD19 mAb | Phase I (NCT00983619) |
| Phase II (with ICE/DHAP NCT01453205) | ||
| Phase II (with PD-1 inhibitor NCT02271945) | ||
| MPDL3280A | Targets PD-L1 expressed on tumor cells and tumor-infiltrating immune cells | Phase I (with Obinutuzumab NCT02220842) |
| Polatuzumab vedotin | Antibody-drug conjugate that targets CD 79b on the B cell receptor complex | Phase II (with Rituximab or Obinutuzumab and Bendamustine NCT02257567) |
| Obinutuzumab (GA101) | Fully humanized IgG1 mAb that selectivity binds to the extracellular domain of the human CD20 antigen on malignant human B cells | Phase Ib/II (with lenalidomide NCT01582776) Phase Ib/II (with lenalidomide NCT01995669) |
| Veltuzumab | A fully humanized mAb directed against the CD20 antigen. | Phase I/II (NCT01147393) |
| ABT-199 | Oral selective small molecule inhibitor of the anti-apoptotic protein Bcl-2 | Phase I (NCT02055820) |
| Phase I (with BR NCT01594229) | ||
| Phase II (with BR vs BR alone NCT02187861) | ||
| Alisertib | Oral selective small molecule inhibitor of the serine/threonine protein kinase Aurora A kinase | Phase I (with Romidepsin NCT01897012) |
| Phase I (with Vorinostat NCT01567709) | ||
| Phase I (with Bortezomib and Rituximab NCT01695941) Phase II (with +/- Rituximab NCT01812005) | ||
| SAR245409 | Oral small molecule targeting the PI3K and mTOR kinases. | Phase I/II (NCT01587040) |
| Belinostat | HDAC inhibitor | Phase I (with Carfilzomib NCT02142530) |
| Phase II (with Ibritumomab Tiuxetan NCT01686165) |
P- Reviewer: Fourtounas C, Marino IR S- Editor: Tian YL L- Editor: A E- Editor: Jiao XK
| 1. | Pasquini M, Wang Z, Horowitz MM, Gale RP. 2013 report from the Center for International Blood and Marrow Transplant Research (CIBMTR): current uses and outcomes of hematopoietic cell transplants for blood and bone marrow disorders. Clin Transpl. 2013;187-197. [PubMed] [Cited in This Article: ] |
| 2. | Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, Sonneveld P, Gisselbrecht C, Cahn JY, Harousseau JL. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med. 1995;333:1540-1545. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 1779] [Cited by in F6Publishing: 1707] [Article Influence: 58.9] [Reference Citation Analysis (0)] |
| 3. | Vose JM, Zhang MJ, Rowlings PA, Lazarus HM, Bolwell BJ, Freytes CO, Pavlovsky S, Keating A, Yanes B, van Besien K. Autologous transplantation for diffuse aggressive non-Hodgkin’s lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol. 2001;19:406-413. [PubMed] [Cited in This Article: ] |
| 4. | Mounier N, Canals C, Gisselbrecht C, Cornelissen J, Foa R, Conde E, Maertens J, Attal M, Rambaldi A, Crawley C. High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European Blood and Marrow Transplantation Registry. Biol Blood Marrow Transplant. 2012;18:788-793. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 74] [Cited by in F6Publishing: 82] [Article Influence: 6.3] [Reference Citation Analysis (0)] |
| 5. | Hamadani M, Hari PN, Zhang Y, Carreras J, Akpek G, Aljurf MD, Ayala E, Bachanova V, Chen AI, Chen YB. Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2014;20:1729-1736. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 89] [Cited by in F6Publishing: 101] [Article Influence: 10.1] [Reference Citation Analysis (0)] |
| 6. | Fenske TS, Hari PN, Carreras J, Zhang MJ, Kamble RT, Bolwell BJ, Cairo MS, Champlin RE, Chen YB, Freytes CO. Impact of pre-transplant rituximab on survival after autologous hematopoietic stem cell transplantation for diffuse large B cell lymphoma. Biol Blood Marrow Transplant. 2009;15:1455-1464. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 44] [Cited by in F6Publishing: 47] [Article Influence: 3.1] [Reference Citation Analysis (0)] |
| 7. | Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M, Bosly A, Ketterer N, Shpilberg O, Hagberg H. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28:4184-4190. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 1014] [Cited by in F6Publishing: 1143] [Article Influence: 81.6] [Reference Citation Analysis (0)] |
| 8. | Fenske TS, Zhang MJ, Carreras J, Ayala E, Burns LJ, Cashen A, Costa LJ, Freytes CO, Gale RP, Hamadani M. Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality. J Clin Oncol. 2014;32:273-281. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 110] [Cited by in F6Publishing: 114] [Article Influence: 10.4] [Reference Citation Analysis (0)] |
| 9. | Hamadani M. Reappraising the role of autologous transplantation for indolent B-cell lymphomas in the chemoimmunotherapy era: is it still relevant? Bone Marrow Transplant. 2013;48:1013-1021. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis (0)] |
| 10. | Freedman AS, Neuberg D, Mauch P, Soiffer RJ, Anderson KC, Fisher DC, Schlossman R, Alyea EP, Takvorian T, Jallow H. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood. 1999;94:3325-3333. [PubMed] [Cited in This Article: ] |
| 11. | Tarella C, Corradini P, Astolfi M, Bondesan P, Caracciolo D, Cherasco C, Ladetto M, Giaretta F, Ricca I, Vitolo U. Negative immunomagnetic ex vivo purging combined with high-dose chemotherapy with peripheral blood progenitor cell autograft in follicular lymphoma patients: evidence for long-term clinical and molecular remissions. Leukemia. 1999;13:1456-1462. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 1.2] [Reference Citation Analysis (0)] |
| 12. | Tarella C, Zanni M, Magni M, Benedetti F, Patti C, Barbui T, Pileri A, Boccadoro M, Ciceri F, Gallamini A. Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innnovative nei linfomi survey. J Clin Oncol. 2008;26:3166-3175. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 53] [Cited by in F6Publishing: 60] [Article Influence: 3.8] [Reference Citation Analysis (0)] |
| 13. | Arcaini L, Montanari F, Alessandrino EP, Tucci A, Brusamolino E, Gargantini L, Cairoli R, Bernasconi P, Passamonti F, Bonfichi M. Immunochemotherapy with in vivo purging and autotransplant induces long clinical and molecular remission in advanced relapsed and refractory follicular lymphoma. Ann Oncol. 2008;19:1331-1335. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 35] [Cited by in F6Publishing: 38] [Article Influence: 2.4] [Reference Citation Analysis (0)] |
| 14. | Schouten HC, Qian W, Kvaloy S, Porcellini A, Hagberg H, Johnsen HE, Doorduijn JK, Sydes MR, Kvalheim G. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin’s lymphoma: results from the randomized European CUP trial. J Clin Oncol. 2003;21:3918-3927. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 378] [Cited by in F6Publishing: 341] [Article Influence: 16.2] [Reference Citation Analysis (0)] |
| 15. | Vose JM, Carter S, Burns LJ, Ayala E, Press OW, Moskowitz CH, Stadtmauer EA, Mineshi S, Ambinder R, Fenske T. Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the BMT CTN 0401 trial. J Clin Oncol. 2013;31:1662-1668. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 133] [Cited by in F6Publishing: 118] [Article Influence: 10.7] [Reference Citation Analysis (0)] |
| 16. | Cohen S, Kiss T, Lachance S, Roy DC, Sauvageau G, Busque L, Ahmad I, Roy J. Tandem autologous-allogeneic nonmyeloablative sibling transplantation in relapsed follicular lymphoma leads to impressive progression-free survival with minimal toxicity. Biol Blood Marrow Transplant. 2012;18:951-957. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis (0)] |
| 17. | Satwani P, Jin Z, Martin PL, Bhatia M, Garvin JH, George D, Chaudhury S, Talano J, Morris E, Harrison L. Sequential myeloablative autologous stem cell transplantation and reduced intensity allogeneic hematopoietic cell transplantation is safe and feasible in children, adolescents and young adults with poor-risk refractory or recurrent Hodgkin and non-Hodgkin lymphoma. Leukemia. 2015;29:448-455. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 3.2] [Reference Citation Analysis (0)] |
| 18. | Salles G, Seymour JF, Offner F, López-Guillermo A, Belada D, Xerri L, Feugier P, Bouabdallah R, Catalano JV, Brice P. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011;377:42-51. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 814] [Cited by in F6Publishing: 766] [Article Influence: 58.9] [Reference Citation Analysis (0)] |
| 19. | Kahl BS, Hong F, Williams ME, Gascoyne RD, Wagner LI, Krauss JC, Habermann TM, Swinnen LJ, Schuster SJ, Peterson CG. Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402. J Clin Oncol. 2014;32:3096-3102. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 129] [Cited by in F6Publishing: 129] [Article Influence: 12.9] [Reference Citation Analysis (0)] |
| 20. | Kluin-Nelemans HC, Hoster E, Hermine O, Walewski J, Trneny M, Geisler CH, Stilgenbauer S, Thieblemont C, Vehling-Kaiser U, Doorduijn JK. Treatment of older patients with mantle-cell lymphoma. N Engl J Med. 2012;367:520-531. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 370] [Cited by in F6Publishing: 361] [Article Influence: 30.1] [Reference Citation Analysis (0)] |
| 21. | Lim SH, Esler WV, Zhang Y, Zhang J, Periman PO, Burris C, Townsend M. B-cell depletion for 2 years after autologous stem cell transplant for NHL induces prolonged hypogammaglobulinemia beyond the rituximab maintenance period. Leuk Lymphoma. 2008;49:152-153. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 1.6] [Reference Citation Analysis (0)] |
| 22. | Zhang W, Jiao L, Zhou DB, Shen T. Rituximab purging and maintenance therapy combined with autologous stem cell transplantation in patients with diffuse large B-cell lymphoma. Oncol Lett. 2010;1:733-738. [PubMed] [Cited in This Article: ] |
| 23. | Tsirigotis P, Dray L, Resnick IB, Ackerstein A, Gesundheit B, Elad S, Or R, Shapira MY. Post-autologous stem cell transplantation administration of rituximab improves the outcome of patients with aggressive B cell non-Hodgkin’s lymphoma. Ann Hematol. 2010;89:263-272. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis (0)] |
| 24. | Haioun C, Mounier N, Emile JF, Ranta D, Coiffier B, Tilly H, Récher C, Fermé C, Gabarre J, Herbrecht R. Rituximab versus observation after high-dose consolidative first-line chemotherapy with autologous stem-cell transplantation in patients with poor-risk diffuse large B-cell lymphoma. Ann Oncol. 2009;20:1985-1992. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 57] [Cited by in F6Publishing: 57] [Article Influence: 3.8] [Reference Citation Analysis (0)] |
| 25. | Gisselbrecht C, Schmitz N, Mounier N, Singh Gill D, Linch DC, Trneny M, Bosly A, Milpied NJ, Radford J, Ketterer N. Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma. J Clin Oncol. 2012;30:4462-4469. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 196] [Cited by in F6Publishing: 201] [Article Influence: 16.8] [Reference Citation Analysis (0)] |
| 26. | Armand P, Nagler A, Weller EA, Devine SM, Avigan DE, Chen YB, Kaminski MS, Holland HK, Winter JN, Mason JR. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. J Clin Oncol. 2013;31:4199-4206. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 352] [Cited by in F6Publishing: 365] [Article Influence: 33.2] [Reference Citation Analysis (0)] |
| 27. | Heutte N, Haioun C, Feugier P, Coiffier B, Tilly H, Ferme C, Gabarre J, Morschhauser F, Gisselbrecht C, Mounier N. Quality of life in 269 patients with poor-risk diffuse large B-cell lymphoma treated with rituximab versus observation after autologous stem cell transplant. Leuk Lymphoma. 2011;52:1239-1248. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis (0)] |
| 28. | Pfreundschuh M, Poeschel V, Zeynalova S, Hänel M, Held G, Schmitz N, Viardot A, Dreyling MH, Hallek M, Mueller C. Optimization of rituximab for the treatment of diffuse large B-cell lymphoma (II): extended rituximab exposure time in the SMARTE-R-CHOP-14 trial of the german high-grade non-Hodgkin lymphoma study group. J Clin Oncol. 2014;32:4127-4133. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 66] [Cited by in F6Publishing: 64] [Article Influence: 6.4] [Reference Citation Analysis (0)] |
| 29. | Andorsky DJ, Yamada RE, Said J, Pinkus GS, Betting DJ, Timmerman JM. Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells. Clin Cancer Res. 2011;17:4232-4244. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 247] [Cited by in F6Publishing: 260] [Article Influence: 20.0] [Reference Citation Analysis (0)] |
| 30. | Li Y, Wang J, Li C, Ke XY. Contribution of PD-L1 to oncogenesis of lymphoma and its RNAi-based targeting therapy. Leuk Lymphoma. 2012;53:2015-2023. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 2.8] [Reference Citation Analysis (0)] |
| 31. | Green MR, Monti S, Rodig SJ, Juszczynski P, Currie T, O’Donnell E, Chapuy B, Takeyama K, Neuberg D, Golub TR. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood. 2010;116:3268-3277. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 893] [Cited by in F6Publishing: 925] [Article Influence: 66.1] [Reference Citation Analysis (0)] |
| 32. | Rosenwald A, Wright G, Leroy K, Yu X, Gaulard P, Gascoyne RD, Chan WC, Zhao T, Haioun C, Greiner TC. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med. 2003;198:851-862. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 842] [Cited by in F6Publishing: 753] [Article Influence: 35.9] [Reference Citation Analysis (0)] |
| 33. | Warlick ED, Tomblyn M, Cao Q, Defor T, Blazar BR, Macmillan M, Verneris M, Wagner J, Dusenbery K, Aurora M. Reduced-intensity conditioning followed by related allografts in hematologic malignancies: long-term outcomes most successful in indolent and aggressive non-Hodgkin lymphomas. Biol Blood Marrow Transplant. 2011;17:1025-1032. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 2.1] [Reference Citation Analysis (0)] |
| 34. | Ansell SM, Stenson M, Habermann TM, Jelinek DF, Witzig TE. Cd4+ T-cell immune response to large B-cell non-Hodgkin’s lymphoma predicts patient outcome. J Clin Oncol. 2001;19:720-726. [PubMed] [Cited in This Article: ] |
| 35. | Guillaume T, Rubinstein DB, Symann M. Immune reconstitution and immunotherapy after autologous hematopoietic stem cell transplantation. Blood. 1998;92:1471-1490. [PubMed] [Cited in This Article: ] |
| 36. | Porrata LF, Litzow MR, Markovic SN. Immune reconstitution after autologous hematopoietic stem cell transplantation. Mayo Clin Proc. 2001;76:407-412. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 59] [Cited by in F6Publishing: 43] [Article Influence: 1.9] [Reference Citation Analysis (0)] |
| 37. | Mathews Griner LA, Guha R, Shinn P, Young RM, Keller JM, Liu D, Goldlust IS, Yasgar A, McKnight C, Boxer MB. High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells. Proc Natl Acad Sci USA. 2014;111:2349-2354. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 287] [Cited by in F6Publishing: 288] [Article Influence: 28.8] [Reference Citation Analysis (0)] |
| 38. | Montoto S, Canals C, Rohatiner AZ, Taghipour G, Sureda A, Schmitz N, Gisselbrecht C, Fouillard L, Milpied N, Haioun C. Long-term follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study. Leukemia. 2007;21:2324-2331. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 116] [Cited by in F6Publishing: 124] [Article Influence: 7.3] [Reference Citation Analysis (0)] |
| 39. | van Besien K, Loberiza FR, Bajorunaite R, Armitage JO, Bashey A, Burns LJ, Freytes CO, Gibson J, Horowitz MM, Inwards DJ. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood. 2003;102:3521-3529. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 278] [Cited by in F6Publishing: 246] [Article Influence: 11.7] [Reference Citation Analysis (0)] |
| 40. | van Oers MH, Klasa R, Marcus RE, Wolf M, Kimby E, Gascoyne RD, Jack A, Van’t Veer M, Vranovsky A, Holte H. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood. 2006;108:3295-3301. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 469] [Cited by in F6Publishing: 498] [Article Influence: 27.7] [Reference Citation Analysis (0)] |
| 41. | van Oers MH, Van Glabbeke M, Giurgea L, Klasa R, Marcus RE, Wolf M, Kimby E, van t Veer M, Vranovsky A, Holte H. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin’s lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol. 2010;28:2853-2858. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 225] [Cited by in F6Publishing: 242] [Article Influence: 17.3] [Reference Citation Analysis (0)] |
| 42. | Pettengell R, Schmitz N, Gisselbrecht C, Smith G, Patton WN, Metzner B, Caballero D, Tilly H, Walewski JA, Bence-Bruckler I. Rituximab purging and/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol. 2013;31:1624-1630. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 96] [Cited by in F6Publishing: 101] [Article Influence: 9.2] [Reference Citation Analysis (0)] |
| 43. | Vitolo U, Ladetto M, Boccomini C, Baldini L, De Angelis F, Tucci A, Botto B, Chiappella A, Chiarenza A, Pinto A. Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: a phase III randomized study by the Fondazione Italiana Linfomi. J Clin Oncol. 2013;31:3351-3359. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 42] [Cited by in F6Publishing: 48] [Article Influence: 4.4] [Reference Citation Analysis (0)] |
| 44. | Martinelli G, Schmitz SF, Utiger U, Cerny T, Hess U, Bassi S, Okkinga E, Stupp R, Stahel R, Heizmann M. Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. J Clin Oncol. 2010;28:4480-4484. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 176] [Cited by in F6Publishing: 191] [Article Influence: 13.6] [Reference Citation Analysis (0)] |
| 45. | Dietrich S, Tielesch B, Rieger M, Nickelsen M, Pott C, Witzens-Harig M, Kneba M, Schmitz N, Ho AD, Dreger P. Patterns and outcome of relapse after autologous stem cell transplantation for mantle cell lymphoma. Cancer. 2011;117:1901-1910. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 2.6] [Reference Citation Analysis (0)] |
| 46. | Lim SH, Esler WV, Periman PO, Beggs D, Zhang Y, Townsend M. R-CHOP followed by consolidative autologous stem cell transplant and low dose rituxan maintenance therapy for advanced mantle cell lymphoma. Br J Haematol. 2008;142:482-484. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis (0)] |
| 47. | Graf SA, Stevenson PA, Holmberg LA, Till BG, Press OW, Chauncey TR, Smith SD, Philip M, Orozco JJ, Shustov AR, Green DJ, Libby EN, Bensinger WI, Pagel JM, Maloney DG, Zhou Y, Cassaday RD, Gopal AK. Rituximab maintenance therapy after autologous stem cell transplantation improves survival of patients with mantle cell lymphoma. 2014 ASH Annual Meeting; San Francisco, CA, December 6-9, 2014. . [Cited in This Article: ] |
| 48. | Dietrich S, Weidle J, Rieger M, Meissner J, Radujkovic A, Ho AD, Dreger P, Witzens-Harig M. Rituximab maintenance therapy after autologous stem cell transplantation prolongs progression-free survival in patients with mantle cell lymphoma. Leukemia. 2014;28:708-709. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 2.5] [Reference Citation Analysis (0)] |
| 49. | Gouill SL, Thieblemont C, Oberic L, Bouabdallah K, Gyan E, Damaj G, Ribrag V, Bologna S, Gressin R, Casasnovas O. Rituximab Maintenance Versus Wait and Watch after Four Courses of R-DHAP Followed by Autologous Stem Cell transplantation in Previously Untreated Young Patients with Mantle Cell Lymphoma: First Interim Analysis of the Phase III Prospective Lyma Trial, a Lysa Study. 2014;ASH Annual Meeting; San Francisco, CA, December 6-9, 2014. [Cited in This Article: ] |
| 50. | Goy A, Sinha R, Williams ME, Kalayoglu Besisik S, Drach J, Ramchandren R, Zhang L, Cicero S, Fu T, Witzig TE. Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. J Clin Oncol. 2013;31:3688-3695. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 248] [Cited by in F6Publishing: 267] [Article Influence: 24.3] [Reference Citation Analysis (0)] |
| 51. | Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369:507-516. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 1178] [Cited by in F6Publishing: 1223] [Article Influence: 111.2] [Reference Citation Analysis (0)] |
| 52. | Andersen NS, Pedersen LB, Laurell A, Elonen E, Kolstad A, Boesen AM, Pedersen LM, Lauritzsen GF, Ekanger R, Nilsson-Ehle H. Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma. J Clin Oncol. 2009;27:4365-4370. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 100] [Cited by in F6Publishing: 107] [Article Influence: 7.1] [Reference Citation Analysis (0)] |